Press Release: Tris Pharma : Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

Tris Pharma: Tris Pharma eyes approval after pain drug triumphs in second Phase III trial

Tris Pharma: Tris Pharma reports positive data from Phase III acute pain therapy trial